Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487997 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL16596401 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL3622973 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL6901715 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL3614645 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL589418 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL2926856 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL22882627 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL21753957 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 | |
| SCHEMBL23093971 | 0.92 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4DNM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022194587-A2 | METHOD FOR THE RECYCLING OF ORGANIC POLYMERS | EVONIK OPERATIONS GMBH (DE) | 2022-09-22 | — | — | WO | claimed |
| US-20210039158-A1 | USE OF AMINE BLENDS FOR FOUNDRY SHAPED CORES AND CASTING METALS | ARKEMA FRANCE (FR) | 2021-02-11 | — | — | US | claimed |
| CN-105939736-B | Odor masking amine compositions | 阿肯马法国公司 | 2020-11-06 | — | — | CN | claimed |
| EP-3102249-B1 | ODOUR-MASKED AMINE COMPOSITION | ARKEMA FRANCE (FR) | 2019-10-16 | — | — | EP | claimed |
| US-10315982-B2 | Odour-masked amine composition | ARKEMA FRANCE (FR) | 2019-06-11 | — | — | US | claimed |
| EP-2106310-B1 | USE OF AMINE BLENDS FOR FOUNDRY SHAPED CORES AND CASTING METALS | ARKEMA FRANCE (FR) | 2019-05-22 | — | — | EP | claimed |
| EP-3102249-A1 | ODOUR-MASKED AMINE COMPOSITION | Arkema France (FR) | 2016-12-14 | — | — | EP | claimed |
| US-20160340292-A1 | ODOUR-MASKED AMINE COMPOSITION | ARKEMA FRANCE (FR) | 2016-11-24 | — | — | US | claimed |
| US-20160067768-A1 | USE OF AMINE BLENDS FOR FOUNDRY SHAPED CORES AND CASTING METALS | ARKEMA FRANCE (FR) | 2016-03-10 | — | — | US | claimed |
| WO-2015118254-A1 | ODOUR-MASKED AMINE COMPOSITION | ARKEMA FRANCE (FR) | 2015-08-13 | — | — | WO | claimed |
| US-20100126690-A1 | USE OF AMINE BLENDS FOR FOUNDRY SHAPED CORES AND CASTING METALS | ARKEMA FRANCE (FR) | 2010-05-27 | — | — | US | claimed |
| EP-2106310-A1 | USE OF AMINE BLENDS FOR FOUNDRY SHAPED CORES AND CASTING METALS | ARKEMA FRANCE (FR) | 2009-10-07 | — | — | EP | claimed |
| WO-2008090161-A1 | USE OF AMINE BLENDS FOR FOUNDRY SHAPED CORES AND CASTING METALS | ARKEMA FRANCE (FR) | 2008-07-31 | — | — | WO | claimed |
| US-12378127-B2 | Silica sol having particle size distribution and production method therefor | NISSAN CHEMICAL CORPORATION (JP) | 2025-08-05 | — | — | US | disclosed |
| EP-4328182-B1 | SILICA SOL HAVING PARTICLE SIZE DISTRIBUTION, AND METHOD FOR MANUFACTURING SAME | NISSAN CHEMICAL CORP (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-12359039-B2 | Metal oxide particle-containing composition with reduced occurrence of volatile aldehydes | NISSAN CHEMICAL CORPORATION (JP) | 2025-07-15 | — | — | US | disclosed |
| US-5973166-A | SUBJECTING N-MALEIMIC ACID IN SUITABLE REACTION MEDIUM TO ACONDITIONS SUFFICIENT TO PROMOTE CYCLODEHYDRATION USING SUBSTITUTED AMINE OR QUATERNARYAMMONIUM SALT CONTAINING CATION AND ANION AS POLARITY MODIFIER AND AN ACID CATALYST | THE DEXTER CORPORATION (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1993013801-A1 | TREATMENT FOR ATHEROSCLEROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-07-22 | — | — | WO | disclosed |
| EP-0206621-B1 | PROCESS FOR DISPROPORTIONATING SILANES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-11-15 | — | — | EP | disclosed |
| EP-0206621-A1 | Process for disproportionating silanes | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340292-A1 | ODOUR-MASKED AMINE COMPOSITION | OR51E2, OR10J3, PNMT | ALDH1A1 480/4885TDP1 3729/4885CYP3A4 441/4885 |
| US-10315982-B2 | Odour-masked amine composition | OR51E2, OR10J3, CHRM1 | ALDH1A1 494/4885TDP1 4180/4885CYP3A4 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.